SCHEDULE 13G: Mangrove Partners Discloses 6.15% Passive Stake in Anebulo Pharmaceuticals

Mangrove Partners IM, LLC and Nathaniel August have reported a passive beneficial ownership of 6.15% of Anebulo Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Summary

• Mangrove Partners IM, LLC and Nathaniel August collectively beneficially own 2,525,252 shares of Anebulo Pharmaceuticals, Inc. common stock.
• This ownership represents 6.15% of the company's total outstanding common stock.
• The filing is a Schedule 13G, indicating a passive investment, meaning the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The shares are held by Mangrove Partners Master Fund, Ltd., with Mangrove Partners IM, LLC serving as its investment manager and Nathaniel August as its principal.
• The percentage of class is calculated based on 41,084,731 shares outstanding as of December 23, 2024, as reported by Anebulo Pharmaceuticals, Inc. in its Form 8-K.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of passive ownership and generally carries a neutral sentiment, indicating compliance with regulatory requirements rather than positive or negative news about the company's operations or financial performance.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by an institutional fund in a pharmaceutical company, which is a common occurrence in the investment landscape. It reflects a fund's belief in the long-term value of the company without seeking active control.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor holding a passive stake may provide some confidence or signal institutional interest in the company.

Key Dates

Keywords

Anebulo Pharmaceuticals, Mangrove Partners, Nathaniel August, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, ANAB